The Business of Pharmacogenomics: Assessing Biotechnology’s Promise in Quantitative Terms

Abstract

SummaryThis article presents an overview of the valuation strategy constructed by the author, with assistance from former colleagues from Biotechnology Industry Research of Frost & Sullivan, for determining the inherent value of a given genomicsbased therapeutic category of technology. The methodology focuses upon future market opportunities (in prospective sales of pharmaceuticals) and their relevance in terms of current dollars invested in constructing these paradigms.